Anti-LRRK2/Dardarin, N-Terminus Antibody (N138/6)

Name: Anti-LRRK2/Dardarin, N-Terminus Antibody
Brand: NeuroMab
SKU: 75-188
Price: 319.0 USD
Availability: InStock

28 Citations

Our Anti-Dardarin/LRRK2, N-terminus mouse monoclonal primary antibody from NeuroMab is produced in-house from hybridoma clone N138/6. It is KO validated, detects human, mouse, and rat Dardarin/LRRK2, N-terminus, and is purified by Protein A chromatography. It is great for use in ICC, WB.

Immunoblot versus rat brain low-speed pellet (LSP), mouse brain membranes (MBM) and wild-type (WT) and LRRK2 KO mouse samples probed with N138/6 (left) and K89/41 (right) TC supe. Mouse brain samples provided by Xiaojie Li, Ted Dawson and Valina Dawson (Johns Hopkins University).

Species Reactivity

Human, Mouse, Rat

Applications

ICC, IHC, IP, WB

Host Species

Mouse

Available Conjugates

490

550

594

650

Go to Full Product Details

Data Sheet

KO Validated

SKU: 75-188

Volume: 100 µL

Variant

Price:

$319.00

Quantity:

Product Details

Target

Dardarin/LRRK2, N-terminus

Target Description

LRRK2 (also known as PARK8) encodes a protein with 5 putative functional domains: an N-terminal leucine-rich repeat (LRR) domain, a Roc (Ras of complex protein) domain that shares sequence homology to the Ras-related GTPase superfamily, a COR (C-terminal of Roc) domain, a mitogen-activated protein kinase kinase kinase (MAPKKK) domain, and a C-terminal WD40 repeat domain. Mutation in this gene is one of the most common causes of inherited Parkinson disease (Gandhi et al., 2008). LRRK2 was originally identified as a putative disease-causing transcript (DKFZp434H2111) within a 2.6-Mb region encompassing a locus for Parkinson disease-8 (PARK8). Northern blot analysis detected a 9-kb mRNA transcript in all tissues tested, including brain. The authors named the protein product dardarin, derived from the Basque word dardara, meaning tremor. LRRK2/dardarin is also known to positively regulate autophagy through a calcium-dependent activation of the CaMKK/AMPK signaling pathway and together with RAB29, plays a role in the retrograde trafficking pathway for recycling proteins, such as mannose 6 phosphate receptor (M6PR), between lysosomes and the Golgi apparatus in a retromer-dependent manner. LRRK2/PARK8 is also known to regulate neuronal process morphology in the intact central nervous system (CNS) and play a role in synaptic vesicle trafficking.

Format

Purified by Protein A chromatography

Concentration

1 mg/mL

Clonality

Monoclonal

Clone

N138/6

Isotype

IgG1

Applications

ICC, IHC, IP, WB

Host Species

Mouse

Gene Name

LRRK2 PARK8

Molecular Weight

>200 kDa

Antigen

Fusion protein amino acids 1-500 (N-terminus) of human LRRK2 (accession number Q5S007) produced recombinantly in E. Coli

Species Reactivity

Human, Mouse, Rat

Antibody Registry ID

AB_2234791

Storage

Aliquot and store at ≤ -20°C for long term storage. For short term storage, store at 2-8°C. For maximum recovery of product, centrifuge the vial prior to removing the cap.

Physical State

Liquid

Production Notes

Produced by in vitro bioreactor culture of hybridoma line followed by Protein A affinity chromatography. Purified mAbs are >90% specific antibody.

Buffer

10 mM Tris, 50 mM Sodium Chloride, 0.065% Sodium Azide pH 7.116

Dilution Ranges

WB: 1:1000
IHC: 1:500
ICC: 1:500
IP: 10 ug

Conjugate

Unconjugated

Specificity

No cross-reactivity reported

Quality Control

Each new lot of antibody is quality control tested by western blot on rat whole brain lysate and confirmed to stain the expected molecular weight band.

Usage Statement

These antibodies are to be used as research laboratory reagents and are not for use as diagnostic or therapeutic reagents in humans.

Country of Origin

United States

Expiration

24 months from date of receipt

Shipping

Shipped on ice packs

Synonyms

Leucine-rich repeat serine/threonine-protein kinase 2 (EC 2.7.11.1) (Dardarin)

UniProt Details

UniProt (Human): Q5S007
UniProt (Immunogen Species): Q5S007

Product Specific References for Applications and Species

Immunocytochemistry: Mouse
Immunohistochemistry: Mouse | Rat
Immunoprecipitation: Human | Mouse
Proximity Ligation Assay (PLA): Human
Western Blot: Human | Mouse | Rat

Immunocytochemistry: Mouse
PMID	Dilution	Publication
25201882	not listed	Cho, H.J., et al. 2014. Leucine-rich repeat kinase 2 regulates Sec16A at ER exit sites to allow ER-Golgi export.. The EMBO Journal, 2314-2331.
24464040	1:200	Parisiadou, L., et al. 2014. LRRK2 regulates synaptogenesis and dopamine receptor activation through modulation of PKA activity.. Nature Neuroscience, 367-376.

Immunohistochemistry: Mouse
PMID	Dilution	Publication
23560750	1:1000	Davies, P., et al. 2013. Comprehensive characterization and optimization of anti-LRRK2 (leucine-rich repeat kinase 2) monoclonal antibodies.. Biochemical Journal, 101-13.

Immunohistochemistry: Rat
PMID	Dilution	Publication
23560750	1:1000	Davies, P., et al. 2013. Comprehensive characterization and optimization of anti-LRRK2 (leucine-rich repeat kinase 2) monoclonal antibodies.. Biochemical Journal, 101-13.

Immunoprecipitation: Human
PMID	Dilution	Publication
27273569	1:1000	Nucifora, F.C. Jr., et al. 2016. Ubiqutination via K27 and K29 chains signals aggregation and neuronal protection of LRRK2 by WSB1.. Nature Communications, 11792.
22423108	not listed	Xiong, Y., et al. 2012. ArfGAP1 is a GTPase activating protein for LRRK2: reciprocal regulation of ArfGAP1 by LRRK2.. Journal of Neuroscience, 3877-3886.

PLA: Human
PMID	Dilution	Publication
38313055	not listed	Abe, T., et al. 2024. Lysosomal stress drives the release of pathogenic α-synuclein from macrophage lineage cells via the LRRK2-Rab10 pathway. iScience, 108893.

Immunoprecipitation: Mouse
PMID	Dilution	Publication
32919031	2ul	Kuwahara, T., et al. 2020. Roles of lysosomotropic agents on LRRK2 activation and Rab10 phosphorylation. Neurobiology of Disease, 105081.
27273569	1:1000	Nucifora, F.C. Jr., et al. 2016. Ubiqutination via K27 and K29 chains signals aggregation and neuronal protection of LRRK2 by WSB1.. Nature Communications, 11792.
22012985	10ug	Gómez-Suaga, P., et al. 2012. Leucine-rich repeat kinase 2 regulates autophagy through a calcium-dependent pathway involving NAADP.. Human Molecular Genetics, 511-525.
22004453	2.5ug	Doggett, E.A., et al. 2012. Phosphorylation of LRRK2 serines 955 and 973 is disrupted by Parkinson''s disease mutations and LRRK2 pharmacological inhibition.. Journal of Neurochemistry, 37-45.

Western Blot: Human
PMID	Dilution	Publication
27273569	1:1000	Nucifora, F.C. Jr., et al. 2016. Ubiqutination via K27 and K29 chains signals aggregation and neuronal protection of LRRK2 by WSB1.. Nature Communications, 11792.
24947832	not listed	Reyniers, L., et al. 2014. Differential protein-protein interactions of LRRK1 and LRRK2 indicate roles in distinct cellular signaling pathways.. Journal of Neurochemistry, 239-250.
24917786	not listed	Vancraenenbroeck, R., et al. 2014. In silico, in vitro and cellular analysis with a kinome-wide inhibitor panel correlates cellular LRRK2 dephosphorylation to inhibitor activity on LRRK2.. Frontiers in Molecular Neuroscience, 51.
23916833	not listed	Manzoni, C., et al. 2013. Inhibition of LRRK2 kinase activity stimulates macroautophagy.. Biochimica et Biophysica Acta, 2900-2910.

Western Blot: Mouse
PMID	Dilution	Publication
37366237	not listed	Liu, Q., et al. 2023. Regulation of LRRK2 mRNA Stability by ATIC and its Substrate AICAR Through ARE-mediated mRNA Decay in Parkinson's Disease. The EMBO Journal, e113410.
34759048	not listed	Kim, J.W., et al. 2021. Dysregulated mRNA Translation in the G2019S LRRK2 and LRRK2 Knock-Out Mouse Brains. eNeuro, .
30592011	not listed	De Wit, T., et al. 2019. Inhibition of LRRK2 or casein kinase 1 results in LRRK2 protein destabilization. Molecular Neurobiology, 5273-5286.
28321439	not listed	Xiong, Y., et al. 2017. Overexpression of Parkinson's Disease-Associated Mutation LRRK2 G2019S in Mouse Forebrain Induces Behavioral Deficits and α-Synuclein Pathology. eNeuro, .
28103901	1:1000	Berwick, D.C., et al. 2017. Pathogenic LRRK2 variants are gain-of-function mutations that enhance LRRK2-mediated repression of β-catenin signaling.. Molecular Neurodegeneration, 9.
27378696	1:1000	Ma, B., et al. 2016. LRRK2 modulates microglial activity through regulation of chemokine (C-X3-C) receptor 1 -mediated signalling pathways. Human Molecular Genetics, 3515-3523.
27273569	1:1000	Nucifora, F.C. Jr., et al. 2016. Ubiqutination via K27 and K29 chains signals aggregation and neuronal protection of LRRK2 by WSB1.. Nature Communications, 11792.
24464040	1:1000	Parisiadou, L., et al. 2014. LRRK2 regulates synaptogenesis and dopamine receptor activation through modulation of PKA activity.. Nature Neuroscience, 367-376.
23560750	1:1000	Davies, P., et al. 2013. Comprehensive characterization and optimization of anti-LRRK2 (leucine-rich repeat kinase 2) monoclonal antibodies.. Biochemical Journal, 101-13.
23125283	not listed	Cho, H.J., et al. 2013. MicroRNA-205 regulates the expression of Parkinson''s disease-related leucine-rich repeat kinase 2 protein.. Human Molecular Genetics, 608-622.
22899650	not listed	Berwick, D.C., et al. 2012. LRRK2 functions as a Wnt signaling scaffold, bridging cytosolic proteins and membrane-localized LRP6.. Human Molecular Genetics, 4966-4979.
20016100	not listed	Andres-Mateos, E., et al. 2009. Unexpected lack of hypersensitivity in LRRK2 knock-out mice to MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine).. Journal of Neuroscience, 15846-15850.

Western Blot: Rat
PMID	Dilution	Publication
23560750	1:1000	Davies, P., et al. 2013. Comprehensive characterization and optimization of anti-LRRK2 (leucine-rich repeat kinase 2) monoclonal antibodies.. Biochemical Journal, 101-13.

Recover password

Create my account

Anti-LRRK2/Dardarin, N-Terminus Antibody (N138/6)

SKU: 75-188

Product Details

Product Specific References for Applications and Species

Bulk Order Anti-LRRK2/Dardarin, N-Terminus Antibody

Related Products

Recently Viewed